Reply to: "Do IL-17 inhibitors increase risk of respiratory tract infections?"
- PMID: 32622146
- PMCID: PMC7329655
- DOI: 10.1016/j.jaad.2020.06.1001
Reply to: "Do IL-17 inhibitors increase risk of respiratory tract infections?"
Comment on
-
The risk of respiratory tract infections and symptoms in psoriasis patients treated with interleukin 17 pathway-inhibiting biologics: A meta-estimate of pivotal trials relevant to decision making during the COVID-19 pandemic.J Am Acad Dermatol. 2020 Aug;83(2):677-679. doi: 10.1016/j.jaad.2020.05.035. Epub 2020 May 19. J Am Acad Dermatol. 2020. PMID: 32416207 Free PMC article. No abstract available.
-
Reply to: Do interleukin 17 inhibitors increase risk of respiratory tract infections?J Am Acad Dermatol. 2020 Oct;83(4):e303-e304. doi: 10.1016/j.jaad.2020.06.1000. Epub 2020 Jul 1. J Am Acad Dermatol. 2020. PMID: 32622137 Free PMC article. No abstract available.
References
-
- Wan M.T., Shin D.B., Winthrop K.L., Gelfand J.M. The risk of respiratory tract infections and symptoms in psoriasis patients treated with interleukin 17 pathway inhibiting biologics: a meta-estimate of pivotal trials relevant to decision making during the COVID-19 pandemic. J Am Acad Dermatol. 2020;83(2):677–679. - PMC - PubMed
-
- Center for Drug Evaluation and Research. Application number: 125521Orig1s000. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/125521Orig1s000O...
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
